Eli Lilly and Company (LLY)vsTravere Therapeutics Inc (TVTX)
LLY
Eli Lilly and Company
$1,152.93
+0.04%
HEALTHCARE · Cap: $994.92B
TVTX
Travere Therapeutics Inc
$62.76
-3.06%
HEALTHCARE · Cap: $6.24B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 13372% more annual revenue ($79.67B vs $591.33M). LLY leads profitability with a 33.5% profit margin vs -7.3%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
TVTX
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+0.8%
Fair Value
$63.00
Current Price
$62.76
$0.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 48.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.3x book value
0.0% earnings growth
Operating margin of 2.3%
Trading at 58.7x book value
ROE of -69.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : TVTX
The strongest argument for TVTX centers on Revenue Growth. Revenue growth of 48.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : TVTX
The primary concerns for TVTX are EPS Growth, Operating Margin, Price/Book. Debt-to-equity of 25.16 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while TVTX is a hypergrowth play — different risk/reward profiles.
TVTX carries more volatility with a beta of 1.06 — expect wider price swings.
TVTX is growing revenue faster at 48.2% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 31/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Travere Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?